{"id":17241,"date":"2026-06-07T17:04:00","date_gmt":"2026-06-07T15:04:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=62e704db6d1d5936d54e50270e6f74b9"},"modified":"2026-06-07T17:04:00","modified_gmt":"2026-06-07T15:04:00","slug":"shareholder-class-action-reminder-faruqi-faruqi-llp-reminds-grail-gral-investors-of-securities-class-action-deadline-on-august-4-2026","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=17241","title":{"rendered":"SHAREHOLDER CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Deadline on August 4, 2026"},"content":{"rendered":"

Faruqi & Faruqi, LLP Securities Litigation Partner <\/b>James (Josh) Wilson<\/b><\/a> Encourages Investors Who Suffered Losses In Grail To Contact Him Directly To Discuss Their Options<\/b><\/p><\/a><\/a><\/a><\/a>

If you purchased or acquired securities in <\/b>Grail<\/b><\/a> between May 13, 2025 and February 19, 2026 <\/b>and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly <\/b>at 877-247-4292 <\/b>or 212-983-9330 (Ext. 1310)<\/b>.<\/p>

[You may also click here for additional information]<\/b><\/a><\/p>

NEW YORK--(BUSINESS WIRE)--$GRAL<\/a> #ClassAction<\/a>--Faruqi & Faruqi, LLP<\/a>, a leading national securities law firm, is investigating potential claims against Grail, Inc. (\u201cGrail\u201d or the \u201cCompany\u201d) (NASDAQ: GRAL) and reminds investors of the August 4, 2026 deadline<\/b> to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.<\/p>

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com<\/a>.<\/p>

Defendants provided investors with material information concerning the likelihood of success of Grail\u2019s NHS-Galleri trial achieving its primary endpoint of a statistically significant reduction in Stage III & IV cancers. Defendants\u2019 statements included, among other things, confidence in the success of Galleri, consistently promoting its effectiveness \u201cin the real world\u201d and the positive predictive value (\u201cPPV\u201d) observed in the Pathfinder studies and in NHS-Galleri\u2019s top-line results as sources of confidence for its potential. Defendants further routinely touted the design of the NHS-Galleri and how three years were necessary to demonstrate the achievability of the primary endpoint.<\/p>

Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of Grail\u2019s NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as Defendants have since attested, the trial as executed within the three-year follow-up period was insufficient to demonstrate the achievability of a reduction in Stage III-IV cancers; Defendants disclosed the trial period, and thus the screening duration, was apparently insufficient to demonstrate whether the primary endpoint was achievable. Defendants further repeatedly refused to provide detailed topline results or other data from the NHS-Galleri study, potentially concealing known trendlines which arguably suggested either a longer timeline would be necessary or otherwise that the probability of achieving the statistical reduction in Stage III & IV cancers by the trial\u2019s end had been reduced.<\/p>

On February 19, 2026, Grail announced that the \u201cprimary endpoint of statistically significant Stage III-IV reduction was not observed\u201d in the NHS-Galleri Trial. The Company attributed this shortcoming, in part, on \u201cprobably need[ing] a longer follow-up time to be able to [compare the study arms] adequately.\u201d<\/p>

Investors and analysts reacted immediately to Grail\u2019s revelation. The price of Grail\u2019s common stock declined dramatically. From a closing market price of $101.53 per share on February 19, 2026, Grail\u2019s stock price fell to $50.21 per share on February 20, 2026, a decline of about 50.55% in the span of just a single day.<\/p>

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.<\/p>

Faruqi & Faruqi, LLP also encourages anyone with information regarding Grail\u2019s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.<\/p>

To learn more about the Grail<\/b> class action, go to www.faruqilaw.com\/GRAL<\/b><\/a> or call<\/b> Faruqi & Faruqi partner Josh Wilson directly <\/b>at 877-247-4292 <\/b>or 212-983-9330 (Ext. 1310)<\/b>.<\/p>

Follow us for updates on LinkedIn<\/a>, on X<\/a>, or on Facebook<\/a>.<\/p>

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com<\/a>). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.<\/p> Contacts<\/b>

Faruqi & Faruqi, LLPJosh Wilson877-247-4292 or 212-983-9330 (Ext. 1310)<\/p>","protected":false},"excerpt":{"rendered":"

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Grail To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Grail between May 13, 2025 and Febru…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-17241","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17241"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17241\/revisions"}],"predecessor-version":[{"id":17242,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17241\/revisions\/17242"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}